AKT Combination Increased PFS in Metastatic HR-Positive/HER2-Negative Breast Cancer

(MedPage Today) — CHICAGO — Progression-free survival (PFS) in metastatic hormone receptor (HR)-positive breast cancer more than doubled with the AKT inhibitor ipatasertib added to fulvestrant after first-line CDK4/6 inhibition, a randomized…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115871

Author :

Publish date : 2025-06-03 15:20:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

AKT Combination Increased PFS in Metastatic HR-Positive/HER2-Negative Breast Cancer

Do Pregnant Women Need COVID Boosters?

Parenting Training Reduces Healthcare Needs for Kids With Asthma Plus ADHD

Related Posts

Early Switch to Oral Antibiotics Effective in Endocarditis

Does Combination Therapy Increase Infection Risk in PsA?

Vitiligo Tied to Alopecia, RA, Other Autoimmune Diseases

Can CRISPR Help NK Cells Fight Cancer?

‘Forever Chemicals’ Curb Bariatric Surgery Success in Teens

Rapid Care Access Improves Outcomes in HIV

Early Switch to Oral Antibiotics Effective in Endocarditis

Does Combination Therapy Increase Infection Risk in PsA?

Vitiligo Tied to Alopecia, RA, Other Autoimmune Diseases

Can CRISPR Help NK Cells Fight Cancer?

‘Forever Chemicals’ Curb Bariatric Surgery Success in Teens

Rapid Care Access Improves Outcomes in HIV

Digital Data Reveal Altered Walking Patterns in COPD

‘Unless We Take It Seriously, We’ll Die Like This’: What We Heard This Week

Categories

Archives